Newsfeeds - Spark Newswire

5 minute read

Adverum Biotech Saturday Morning Highlighted Will Present Data From Its INFINITY Trial Of ADVM-022 In Patients With Diabetic Macular Edema During American Society of Retina Specialists Meeting Oct. 11 At 9:50 a.m. EDT

Today, 1:58 PM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today is presenting data from the INFINITY clinical trial of ADVM-022 in

ADVM

8 minute read

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

By Shanthi Rexaline

Today, 1:58 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)

ABIO

7 minute read

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results

By Shanthi Rexaline

Today, 1:58 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)

ADVM

4 minute read

44 Biggest Movers From Yesterday

By Lisa Levin

Today, 1:58 PM

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.

ADVM

2 minute read

Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher

By Lisa Levin

Today, 1:58 PM

Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00.

ADVM

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 1:58 PM

ADVM

3 minute read

30 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 1:58 PM

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.

ADVM

1 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 1:58 PM

ADVM

2 minute read

18 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 1:58 PM

Gainers CohBar, Inc. (NASDAQ: CWBR) rose 22.8% to $1.13 in pre-market trading after dropping over 4% on Friday.

ADVM

1 minute read

Adverum’s Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety

By Vandana Singh

Today, 1:58 PM

Adverum Biotechnologies Inc (NASDAQ:ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related…

ADVM